Syndax Pharmaceuticals, Inc. (SNDX) Free cash flow 2016–2025
Syndax Pharmaceuticals, Inc. (SNDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$323.2MFY2025 · since FY2016: -$35.4M → -$323.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$323.2M | -17.6% |
| FY2024 | -$274.9M | -71.2% |
| FY2023 | -$160.6M | -20.1% |
| FY2022 | -$133.7M | -560.9% |
| FY2021 | $29.0M | +140.7% |
| FY2020 | -$71.3M | — |
| FY2018 | -$68.7M | -44.8% |
| FY2017 | -$47.5M | -34.0% |
| FY2016 | -$35.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SNDX financial trends
SNDX RevenueSNDX Net incomeSNDX Net marginSNDX Gross profitSNDX Gross marginSNDX Operating incomeSNDX Operating marginSNDX Operating cash flowSNDX Capital expendituresSNDX Return on equitySNDX Stock buybacksSNDX Dividends paidSNDX Total assetsSNDX Total liabilitiesSNDX Shareholders’ equitySNDX overview →